Scalability vs. Growth While the terms ‘scalability’ and ‘growth’ are often used interchangeably in common business parlance, as metrics in manufacturing, the two are quite distinct. Indeed, growth, which is essentially recognized as an increase in revenue, is both the...
CBD – A Consumer Health Revolution Amidst Regulatory Ambiguity CBD (cannabidiol), one of many cannabinoids derived from the plant Cannabis sativa L. (cannabis) has gained enormous popularity over the last decade. While positive consumer perception of CBD continues to rise...
Vantage Hemp Co. Submits a Drug Master File for CBD Distillate to the U.S. Food & Drug Administration
Vantage Hemp Co. further solidifies its position as an industry leader by its announcement of a DMF submission for its CBD distillate to the FDA.
Dive into the establishment of US hemp policy and the importance of selecting a pharmaceutically proficient CBD extractor and contract manufacturer.
As an active pharmaceutical ingredient (API) manufacturer, Vantage prepares for its DMF submissions to the FDA to support the quality and safety of its products.
The demand for cannabidiol (CBD) is growing fast in the pharmaceutical sector, thanks to increased awareness among consumers about CBD health benefits.
Vantage Hemp Co. is pleased to announce its new partnership with Medcan Australia (Medcan) and expansion into the Australian CBD market
Vantage is a global leader in the production of CBD extracts with its facilities achieving ICH Q7 and WHO Good Manufacturing Practices (GMP) certification.